Genetic and epigenetic alterations contribute to the biological and clinical characteristics of myelodysplastic syndromes (MDS), but a role for socioeconomic environment remains unclear. Here, socioeconomic status (SES) for 283 MDS patients was estimated using the Scottish Index of Multiple Deprivation tool. Indices were assigned to quintile categorical indicators ranked from SES1 (lowest) to SES5 (highest). Clinicopathological features and outcomes between SES quintiles containing 15%, 20%, 19%, 30% and 16% of patients were compared. Prognostic scores identified lower-risk MDS in 82% of patients, with higher-risk disease in 18%.
Introduction
Myelodysplastic syndromes (MDS) are disorders characterised by different levels of bone marrow failure, dysplasia affecting one or more haemopoietic cell lineages and a variable propensity for transformation to acute myeloid leukaemia (AML) (Nimer et al, 2008) . Over the last 40 years, a number of studies have enhanced our understanding of the biology of MDS and increased the accuracy of clinical prognostication (Platzbecker, 2015) . Earlier studies focussed on morphological (Bennett et al, 1982) and cytogenetic characteristics of MDS (Vardiman et al, 2002) , but the advent of molecular sequencing techniques has helped identify acquired gene mutations in majority of MDS patients, with functional clustering that appears to be clinically relevant (Papaemmanuil et al, 2013; Itzykson et al, 2013) . Thus, driver mutations in haemopoietic stem cells contributing to specific sub-types of MDS have been identified, with the acquisition of additional mutations within this cellular compartment or downstream progenitors associating with transformation to AML. In addition, epigenomic deregulation is being increasingly recognised in the pathogenesis of MDS (Itzykson et al, 2013; Itzykson & Fenaux, 2014) . The improved understanding of the biological characteristics of MDS is now enabling therapies which result in haematological improvement (reviewed in Garcia-Manero, 2014) or prolong survival in subsets of patients (Fenaux et al, 2009 ).
Despite the plethora of studies investigating genetic and epigenetic changes in MDS, a possible role for environmental factors in altering disease phenotype and/or influencing outcomes has been less well investigated. Whether phenotypic characteristics and genomic alterations observed in MDS, commonly used for prognostication, are influenced by patient socioeconomic status (SES) is therefore unclear. A role for the environment in influencing leukaemogenesis has been 4 suggested by the differences in the incidence of radiation-induced AML in genetically susceptible mice housed under different conditions (Walburg et al, 1968) . In these animal models, a pro-inflammatory 'by-stander' cell response to radiation creates an in vivo microenvironment favouring AML development (Mukherjee et al, 2014) . If inflammation were similarly important for the development of de novo MDS and AML in humans, SES could be an important contributor to clonal instability since DNA methylation profiling has suggested increased pro-inflammatory gene activity in individuals from lower socioeconomic backgrounds (Stringhini et al, 2015) . Support for an SES-associated effect on disease biology comes from the observation that mutations in the tumour suppressor gene TP53 in breast cancer are overrepresented in women with severe socioeconomic deprivation (Baker et al, 2010; Starks et al, 2013) .
Whether SES can alter outcome trajectories in MDS patients has not been extensively studied. In patients with solid organ and other haematological neoplasia differences in time to diagnosis, access to clinical care or trials and comorbidity between patients that are SES-dependent are known to affect survival (Kolahdooz et al, 2014; Munro, 2005; Roberts et al, 2015; Rutherford et al, 2013) . For example, the lower incidence of childhood acute lymphoblastic leukaemia across levels of increasing relative deprivation could reflect under-diagnosis in lower socioeconomic communities (Kroll et al, 2012; Lightfoot et al, 2012) , and the mortality in AML and myeloma appears to be reduced in higher SES groups in some studies (Kristinsson et al, 2009) . In MDS, studies investigating the effects of SES on outcomes (Wang et al, 2009; England et al, 2013) have yielded conflicting conclusions, possibly due to differences in healthcare funding or organisational structure of healthcare services.
Studies on patients treated within the National Health Service (NHS) in the United 5 Kingdom are relatively less likely to be confounded by these variables since the NHS is free at the point-of-delivery and based on clinical need and not means-tested. In addition, the delivery of secondary health care by a single treatment centre to all patients within the defined catchment area reduces patient selection bias in singleinstitution studies. These advantages lead us to investigate the effects of SES on clinic-pathological disease characteristics and treatment outcomes including cause of death in MDS patients within NHS Tayside that serves a population of 400,000.
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Methods
Patients
Adults diagnosed with MDS including non-proliferative chronic myelomonocytic leukaemia (CMML) between 1996-2012 were identified from the Tayside MDS Registry that contains relevant information on patients diagnosed and managed in NHS Tayside. This Registry has been established with approval from the Tayside Medical Research Ethics Committee. Patients with incomplete datasets and those with refractory anaemia and excess of blasts in transformation (RAEB-t) were excluded. Patient demographics, date of diagnosis, morphological MDS sub-type (FAB or WHO), karyotype, IPSS score (Greenberg et al, 1997) , AML transformation and date of last follow-up or death were abstracted from the Registry. For acquisition of additional patient data, Caldicott Guardian approval was obtained in compliance with local information governance regulations.
Results of targeted gene sequencing reported previously (Papaemmanuil et al, 2013) were used to map the genomic landscape in 95 patients. To enable comparisons with SES, genes were stratified into three functional groups based on the ability to regulate epigenetics, RNA splicing or transcriptional signalling (Bejar and Steensma, 2014) .
Cause of death
The cause of death was determined from the final progress note by a hospitalbased or community physician. In patients with transformed AML not in remission, 7 AML was identified as the cause of death. Death associated with progressive cytopenias in the absence of circulating blasts, or cachexia was attributed to MDS.
Infections as a cause of death included pneumonia as well as non-pneumonic, systemic sepsis. Patients dying in hospital following surgery were classed as having died of post-surgical complications. Patients older than 80 years, with stable blood counts who experienced sudden death were categorised as having died of ageing.
To investigate associations with SES, causes of death were categorised into those arising as a complication of marrow dysfunction (including pneumonia, infection, bleeding, AML or progressive MDS) or organ failure (cardiac, renal or pulmonary disease). In addition, death due to advanced age, other malignancies, post-surgery, thrombosis, post-operative or unknown causes constituted an 'ancillary' category.
Socioeconomic deprivation data
The SES was inferred from the datazone associated with the patient's residence postcode at the time of diagnosis and the Scottish Index of Multiple Deprivation (SIMD 2009). SIMD is the Scottish Government's official tool for quantifying relative deprivation in Scotland. The tool incorporates several different aspects of deprivation, based on employment, income, health, education, skills and training, geographic access to services, crime and housing and combines these into a single index. Data were derived from the publically available database (http://www.scotland.gov.uk/Topics/Statistics/SIMD/SIMDPostcodeLookup/Scotlan dPostcodeLookup). Indices were assigned to quintile categorical indicators 8 ranked from SES1 (lowest) to SES5 (highest). SES for patients diagnosed in the period prior to the development of the SIMD tool was calculated from the Carstairs index (http://www.isdscotland.org/products-and-Services/GPD-Support/deprivation/carstairs/; Carstairs & Morris, 1990 ) and assigned to quintiles.
Although the Carstairs index uses different criteria, Carstairs SES quintiles ranked from 1 (highest) to 5 (lowest) correlated negatively with those developed using SIMD (p<0.0001) suggesting the ability to identify similar SES groups. For this reason, and likely absence of significant changes in post code-affiliated SES over the time period of the study-patient population, the SIMD 2009 tool was extrapolated to measure area SES in all patients.
Statistical analysis
The potential association between SES and co-variates included in the study: patient demographics (age and gender), clinicopathological characteristics (morphological sub-type of MDS, karyotype, genomic analysis and IPSS) and treatment details was investigated using the Chi Square test. All statistical analysis was performed using R software (Version 3.2). In addition, differences in patient outcomes including AML transformation, overall and leukaemia-free survival and causes of death were compared between SES quintiles. Overall survival (OS) was measured as the time from diagnosis to the time of death or last follow-up; leukaemia-free survival (LFS) was calculated from the times between the diagnosis of MDS and AML diagnosis or time of last follow-up. Survival outcomes were analysed using the log-rank test for Kaplan Meier survival curves.
Cox regression models were used to estimate the hazard ratio for the significant 9 co-variates of both OS and LFS. All p-values were two-tailed and statistical significance was set at the level of p< 0.05. (Table I) Of 305 patients in the registry, 283 Tayside residents were identified as being suitable for the study. Ten local patients were excluded due to insufficient information including absence of marrow examination or failed cytogenetic analysis. the remainder of the patients with intermediate-2 and high-risk MDS had higher-risk disease (n=52). In the 95 patients who underwent genomic analysis, a total of 198 mutations were identified with commonly mutated oncogenes including TET2 (22% of total mutations), SF3B1 (15%), SFRS2 (11%) and ASXL1 (10%). Mutations in U2AF1, DNAMT3A, CBL, RUNX1, EZH2, TP53 and ZRZR2 accounted for 3-6%, NRAS, IDH1, KRAS, PHF6, STAG2, CUX1, EP300 and IDH2, 1-2% and BCOR, CEBPA, GATA2, JAK2, KIT, NF1, PTPN11 and RAD21 for <1% of the mutational spectrum.
Results
Patient demographics and disease characteristics
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Treatment (Table II) The majority of patients (n=257) exclusively received best supportive care (BSC) with blood products and antibiotics for treatment of infections. In 26 patients, disease modifying therapy was used and 4 patients underwent allogeneic stem cell transplantation.
Transformation to AML and the cause of death
Transformation to AML was observed in 53 patients (19%), with the likelihood being greater in higher-risk MDS (21/52) than with lower-risk disease (32/231, X-squared 15.54, df=1, 95% CI for the difference between proportions of transformation 12-40, p<0.0001).
At last follow-up, 247 out of 283 patients (87%) had died. Leukaemictransformation was the most frequent cause of death (22%) in the entire cohort followed by infection (20%) and advanced age (15%). When the causes of death in patients with lower-risk MDS were examined (Table III) , 17% of deaths in this subgroup were related to leukaemic-transformation. Death due to infection including pneumonia (20%), advanced age (16%), progressive MDS (8%), bleeding (7%), nonmyeloid malignancies (7%) and cardiac failure (6%) also accounting for fatalities (Table III) . In higher-risk MDS, death occurred due to leukaemic-transformation (38%), infection (25%), advanced age (11%), bleeding (4%) or progressive MDS (4%). (Table IV) To investigate the association between SES and MDS characteristics at diagnosis, patient demographics and clinicopathological variables within different SES quintiles were compared. As shown in Table IV , there was no association between SES and age (X-squared 2.5, df=4, p=0.63) or gender (X-squared=2.4, df=4, p=0.67). A statistical comparison of MDS sub-types and different SES groups was limited by small numbers in some MDS sub-groups. We therefore investigated whether a diagnosis of RA compared to other forms of MDS (non-RA MDS) associated with SES, since the absence of excess blasts, uni-lineage cytopenia and dysplasia can make the diagnosis of RA more challenging than other MDS sub-types (Schiffer, 2006; Malcovati et al, 2013) . By Chi-square test, a significant association between RA and SES was detected (X-squared=11.16, df=4, p=0.024). Using ordinal regression modelling for the relation between SES and RA, the odds ratio of a diagnosis of RA was almost double that of non-RA in SES5 compared to other SES groups (odds ratio 1.9, CI 1.2-2.9; p=0.024).
SES, MDS phenotype, genomic changes and prognostic scores
There was no significant association between SES and bone marrow karyotype (X-squared=5.3, df=8, p=0.72) or in sub-analysis (n=95) or the frequency of driver mutations in genes regulating epigenetics, RNA splicing or transcription (X-squared=1.4, df=8, p=0.99). The IPSS score too did not associate with SES, with lower-and higher risk-groups featuring equally in different SES quintiles (X-squared=6.0482, df=4, p=0.19).
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SES, treatment and disease outcomes
Disease modifying therapy for lower-risk MDS was offered to 1, 0, 2, 4 and 6 patients in SES quintiles 1-5 respectively; corresponding patient numbers treated for higherrisk MDS were 4, 4, 2, 2 and 1 respectively. These numbers limited a statistically valid investigation of an association between SES and therapy. No association was observed between SES and leukaemic-transformation (X-squared=2.63, df=4, p=0.62) or the cause of death (X-squared=6.49, df=8, p=0.59) (Table IV) .
Median survival of the entire cohort was 28.5 months (95% CI 24.6% -35.0%, range, 0.10-280) ( Figure 1A) . In a log-rank test of OS, age >70 years (p=0.006), higher-risk MDS (p<0.0001), male gender (p=0.022) and transformation to AML (p=0.0003) significantly decreased OS. Multiple Cox regression models were fitted for the covariates from the univariate analysis and identified male gender (HR 1.3, 95% CI 1.0-1.7, p=0.04), lower-risk disease (HR 0.38, 95% CI 0.27-0.53, p<0.0001, Figure 1B) , age ≤70 years (HR 0.59, 95% CI 0.44-0.80, p=0.0007) and AML transformation (HR 1.35, 95% CI 0.97-1.99, p=0.07) as being independent predictors of OS. SES had not influence the OS of the entire cohort (p=0.37) or of patients with lower-risk ( Figure 1C ) and higher-risk MDS ( Figure 1D ).
The median LFS was 27.9 months (95% CI 23. 6-34.1, range (0.1-199 Figure 1C and D), male (HR 1.29, 95% CI 0.99-1.67 p=.051) and age (HR 0.61, 95% CI 0.45-0.83, p=0.02) as independent predictors of LFS.
Discussion
Based on the established SES-dependent variation in clinicopathological characteristics and outcomes in many diseases (Barker, 1981; Gomez et al, 2015; Stringhini et al, 2013) including cancer (DeSantis et al, 2011; Kolahdooz et al, 2014; Lyratzopoulos et al, 2012; Roberts et al, 2015; Rutherford et al, 2013) , we hypothesised a role for SES in influencing the biological and clinical heterogeneity in patients with MDS. In previous studies, Wang et al (2009) investigated the prognostic role of neighbourhood SES in MDS using data from the Surveillance, Epidemiology and End Results (SEER) cancer registries linked to the national insurance programme Medicare in the USA and identified poorer survival in patients belonging to lower SES groups. While this epidemiological study included a large number of patients, its relevance to areas with alternative mechanisms of health funding is unclear since affordability of therapy can confound interpretation of socioeconomic influences on cancer outcomes. The predictors of survival we have identified in Cox-regression analyses are not new, but importantly, these validate our dataset and its suitability for models to investigate associations between SES and MDS. Thus, the comparable survival outcomes between patients from different SES in our study, combined with the observations from a Canadian cohort of patients (England et al, 2013 ) strongly indicate the ability of equitable healthcare access in MDS to negate adverse outcomes associated with socioeconomic deprivation (Wang et al, 2009 ).
When specific outcomes were studied, in contrast to the study by England et al, (2013) , we were unable to demonstrate leukaemic-transformation as being more frequent in patients of higher SES. Since all MDS patients in Tayside are treated within NHS Tayside hospitals, the possibility of referral patterns introducing bias in 16 the Canadian study should be considered. We also failed to identify a contributory role for SES in influencing mortality patterns in both lower and higher risk MDS. In particular, cardiovascular mortality, known to associate inversely with socioeconomic deprivation (Ramsay et al, 2015) was low (Dayyani et al, 2010) and equally represented in the SES quintiles. Since cardiovascular deaths in MDS patients raise concerns about transfusion-associated iron overload, it would be important to state that barring one patient, the others had significant cardiovascular and valvular disease at the time of MDS diagnosis. Unfortunately, data on co-morbidity on all 283 patients in our cohort was not available, preventing a comprehensive evaluation of its association with SES and contribution to choice of therapy and outcomes.
However, the analysis of co-morbidity in a subset of higher-risk patients included in a previous study (Durairaj et al, 2013) did not identify any obvious differences in comorbidity patterns between SES quintiles.
When the morphological MDS sub-type was related to SES, uniquely, RA was more frequently diagnosed in patients from higher SES. Since a diagnosis of RA relative to other MDS phenotypes can often be challenging, it is possible that some patients classed as having RA may not have had true MDS. However, RA patients who were screened for driver mutations all had detectable genomic lesions, validating the morphological diagnosis of RA. Relevant to the possible association of morphological sub-type of MDS with SES, a case-control study from China has suggested that the MDS phenotype can be influenced by occupation, life-style and educational status (generally associated with specific socioeconomic groups), with tobacco smoking, exposure to agricultural chemicals and lower educational achievements associating with RCMD and RAEB (Lv et al, 2011) . However, the frequency of MDS sub-types by morphology in the Chinese population is not comparable to that in the West, referral and reporting bias may have skewed Lv et al's study and a clear environmental pre-disposition is absent in an overwhelming majority of MDS patients (Bowen, 2013) . Additional studies would be helpful to confirm the association between morphological sub-types of MDS and SES.
In keeping with observations from other studies (Wang et al, 2009; England et al, 2013) , no cytogenetic features or MDS risk scores are unique to patients within specific SES quintiles. Oncogenic gene mutations believed to drive the disease process in MDS also do not have an obvious association with SES when genes are grouped according to function: mutations in genes responsible for RNA splicing, regulation of the epigenome or transcription were equally represented in patients from different SES. In breast cancer, it has been suggested that TP53 mutations may be over-represented in women facing extreme socioeconomic deprivation (Baker et al, 2010; Starks et al, 2013) . The absence of an obvious genomic link with SES in MDS here could reflect the existence of associations that are unique to a particular malignancy, limited patient numbers or differences in study criteria and analytical models.
The decision to use the SIMD tool to identify area SES and assign SES warrants comment since criteria used to calculate SES often differ between studies.
The assigning of any given deprivation score is derived from a person's social characteristics. Thus, information gathered by census, questionnaires or descriptive accounts can all be used to categorise people into ranks of most to least deprived.
The SIMD tool uses location as an indicator of deprivation, assuming that people living in the same area (postcode-derived datazones) have broadly similar social circumstances. By using data from seven domains relating to multiple aspects of life, an index that helps create the fullest possible picture of deprivation across Scotland is generated. The SIMD thus provides a means of analysing deprivation using a national reference. Other tools such as the Carstairs index (Carstairs & Morris, 1990) are often used in similar studies, but this was deemed unsuitable due to the limited data available for the time-periods encompassed by this study.
However, for patients whose date of diagnosis permitted an evaluation of deprivation using both the SIMD and Carstairs tools, the SES score based on the Carstairs index was comparable to SIMD data, indicating the applicability of the SIMD tool to historic patients. SIMD 2009 was chosen for this study as this version of the SIMD tool reflected best the time period in which most patients in the study cohort had been diagnosed.
A limitation of our study is the absence of data on historic area SES in individual patients since a comprehensive analysis of SES and MDS biology and phenotype would mandate the identification of deprivation most representative of a patient's socio-economic history prior to the diagnosis of MDS. The challenges posed by a review of each patient's social history and mobility meant that the patient's postcode at the time of diagnosis became a surrogate for lifetime location. Therefore the SIMD index will not reflect social mobility, or account for potential anomalies in deprivation within datazones. It is unlikely that standardised patient datasets that include detailed biological variables, on which assessment tools that uniformly assess life-time patient SES in different populations will ever be developed.
Thus, while our study has some limitations, it does succeed in establishing the absence of SES influences on MDS outcomes in a health-system providing equitable care, at least in patients exclusively receiving supportive treatments. Whether potentially modifiable, environmental risk factors influence outcomes in MDS patients on therapy remain of interest.
